In the present study, we aimed to assess the immunoexpressions of PD-L1 and EZH2 in ECs and evaluate their associations with key clinicopathological parameters, including patients’ age, tumour grade and stage, depth of myometrial invasion, histological subtype, and survival outcomes. This evidence concerns the gene EZH2 and neoplasm.